Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 16.06.2023 · 108 (7) · e474-e479
DOI: 10.1210/clinem/dgad001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 06.01.2023. Verfasst von Ghadeer Alhamar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Endocrinology & Diabetes Unit, Università Campus Bio-Medico di Roma, 00128 Rome, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Foundation for the Study of Diabetes, Italian Ministry of Health, ESPEN research fellowship.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D).
Objective
This work aimed to assess the effect of prevaccination glucose control on antibody response to the SARS-CoV-2 vaccine BNT162b2 in T1D.
Methods
We studied 26 patients with T1D scheduled to receive 2 doses, 21 days apart, of BNT162b2, followed prospectively for 6 months with regular evaluation of SARS-CoV-2 antibodies and glucose control. Immunoglobulin G (IgG) to spike glycoprotein were assessed by enzyme-linked immunosorbent assay, and serum neutralization by a live SARS-CoV-2 assay (Vero E6 cells system). Glycated hemoglobin A1c (HbA1c) and continuous glucose monitoring (CGM), including time in range (TIR) and above range (TAR), were collected. The primary exposure and outcome measures were prevaccination glucose control, and antibody response after vaccination, respectively.
Results
Prevaccination HbA1c was unrelated to postvaccine spike IgG (r = −0.33; P = .14). Of note, the CGM profile collected during the 2 weeks preceding BNT162b2 administration correlated with postvaccine IgG response (TIR: r = 0.75; P = .02; TAR: r = −0.81; P = .008). Patients meeting the recommended prevaccination glucose targets of TIR (≥ 70%) and TAR (≤ 25%) developed stronger neutralizing antibody titers (P < .0001 and P = .008, respectively), regardless of HbA1c. Glucose control along the study time frame was also associated with IgG response during follow-up (TIR: r = 0.93; P < .0001; TAR: r = −0.84; P < .0001).
Conclusion
In T1D, glucose profile during the 2 weeks preceding vaccination is associated with stronger spike antibody binding and neutralization, highlighting a role for well-controlled blood glucose in vaccination efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Endocrinology & Diabetes Unit, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
- Dasman Diabetes Institute, 15462 Kuwait City, Kuwait.
- Dipartimento di Medicina Sperimentale, Università degli Studi della Campania "Luigi Vanvitelli," 80138 Naples, Italy.
- Dipartimento di Medicina Chirurgia ed Odontoiatria "Scuola Medica Salernitana," Università degli Studi di Salerno, 84081 Baronissi, Italy.
- Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore," Consiglio Nazionale delle Ricerche, 80131 Naples, Italy.
- Unità di Neuroimmunologia, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione Santa Lucia, 00179 Rome, Italy.
ORCID-Profile: Viola Viola, Giuseppe Matarese, Rocky Strollo
Förderung
- European Foundation for the Study of Diabetes
- Italian Ministry of Health
- ESPEN research fellowship
- Fondazione Italiana Sclerosi Multipla
- Progetti di Rilevante Interesse Nazionale
- Ministero della Salute
- Novo Nordisk Programme for Diabetes Research in Europe 2020
Zitieren
APA
Alhamar, G., Briganti, S., Maggi, D., Viola, V., Faraj, M., Zannella, C., Galdiero, M., Franci, G., Fusco, C., Isgrò, C., Leanza, G., Malandrucco, I., Spinelli, A., Tramontana, F., Iaria, D., Tortoriello, R., Pieralice, S., Rosati, M., Matarese, G., …, & Strollo, R. (2023). Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 108(7), e474-e479. https://doi.org/10.1210/clinem/dgad001
Vancouver
Alhamar G, Briganti S, Maggi D, Viola V, Faraj M, Zannella C, et al. Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023;108(7):e474-e479. doi:10.1210/clinem/dgad001
BibTeX
@article{Alhamar2023,
author = {Alhamar, Ghadeer and Briganti, Silvia and Maggi, Daria and Viola, Viola and Faraj, Malak and Zannella, Carla and Galdiero, Massimiliano and Franci, Gianluigi and Fusco, Clorinda and Isgrò, Camilla and Leanza, Giulia and Malandrucco, Ilaria and Spinelli, Andrea and Tramontana, Flavia and Iaria, Domenico and Tortoriello, Rachele and Pieralice, Silvia and Rosati, Milena and Matarese, Giuseppe and Pozzilli, Paolo and Galgani, Mario and Strollo, Rocky},
title = {Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {7},
pages = {e474--e479},
doi = {10.1210/clinem/dgad001}
}
EUVIMED